Combination Chemotherapy in Treating Patients With Metastatic Ovarian Cancer or Non-Small Cell Lung Cancer
Information source: National Cancer Institute (NCI)
Information obtained from ClinicalTrials.gov on May 08, 2007
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Lung Cancer; Neurotoxicity; Ovarian Cancer
Intervention: amifostine trihydrate (Drug); carboplatin (Drug); paclitaxel (Drug); chemoprotection (Procedure); chemotherapy (Procedure); neurotoxicity attenuation (Procedure); supportive care/therapy (Procedure)
Phase: Phase 2
Status: No longer recruiting
Sponsored by: University of California, San Francisco Official(s) and/or principal investigator(s):
Robert J. Ignoffo, PharmD, Study Chair, Affiliation: University of California, San Francisco
Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug and giving the drugs in different combinations may kill more tumor cells.
PURPOSE: Randomized phase II double-blinded trial to study the effectiveness of paclitaxel and carboplatin given with either amifostine or placebo in patients with metastatic stage III or stage IV ovarian cancer or metastatic stage III or stage IV non-small cell lung cancer.
Clinical Details
Official title:
Amifostine (Ethyol) as a Protectant in Metastatic Ovarian and Non-Small Cell Lung Cancer in Paclitaxel/Carboplatin-Treated Patients: A Comparative Trial
Study design: Interventional, Supportive Care
Detailed description:
OBJECTIVES: I. Determine whether patients with metastatic ovarian and non-small cell lung cancer receiving carboplatin and paclitaxel have significantly fewer neuropathic events when treated with amifostine.
OUTLINE: This is a randomized, parallel group, double blind, controlled study. Patients are randomized to either the amifostine or control group. All patients receive intravenous paclitaxel over 3 hours, followed by carboplatin once every 3 weeks for 6 cycles. Patients who are randomized to the amifostine group receive intravenous amifostine administered as a 15 minute infusion 30 minutes prior to paclitaxel therapy. Patients randomized to the control group receive an intravenous placebo solution. Patients are discontinued from the study if they have disease progression or unacceptable toxic effects after 2 cycles of treatment. Patients are followed monthly for 8 months post treatment.
PROJECTED ACCRUAL: A total of 80 patients will be accrued (40 with advanced ovarian cancer and 40 with advanced non-small cell lung cancer) within 2 years.
Eligibility
Minimum age: 18 Years.
Gender(s): Both.
Criteria:
DISEASE CHARACTERISTICS: Histologically proven stage III/IV ovarian or non-small cell lung cancer
PATIENT CHARACTERISTICS: Age: 18 and over Performance Status: ECOG 0-2 Life Expectancy: Not specified Hematopoietic: Absolute neutrophil count at least 1,500/mm3 Platelet count at least 100,000/mm3 Hepatic: Bilirubin no greater than 3. 0 mg/dL Renal: Creatinine no greater than 2 mg/dL Other: Not pregnant or nursing No history of platinum, paclitaxel or amifostine hypersensitivity Prior myelosuppressive events allowed No clinically significant ascites
PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: No prior chemotherapy within 1 month of study Endocrine therapy: Not specified Radiotherapy: No prior radiation therapy within 1 month of study Surgery: Not specified
Locations and Contacts
Oncology Service of San Francisco General Hospital Medical Center, San Francisco, California 94110, United States
UCSF Cancer Center and Cancer Research Institute, San Francisco, California 94115-0128, United States
UCSF/Mt. Zion Cancer Center, San Francisco, California 94115, United States
Veterans Affairs Medical Center - San Francisco, San Francisco, California 94121, United States
Additional Information
Clinical trial summary from the National Cancer Institute's PDQ® database
Starting date:
May 1997
Last updated: February 20, 2007
|
